Finoriq research workspace
Assertio Holdings, Inc. (ASRT) SEC Filings & Filing Highlights
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the. Review ASRT SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
- Company
- Assertio Holdings, Inc. (ASRT)
- Ticker
- ASRT
- Market Cap
- $151.8M
- Latest Price
- $23.5
- Industry
- Biotech & Pharma
Assertio Holdings, Inc. (ASRT) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Assertio Holdings, Inc. (ASRT).
| Event | Form | Date |
|---|---|---|
| The trustee, paying agent and conversion agent for the Notes isAssertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Ou... | 8-K8.01 | 2026-06-16 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-06-16 |
| The information contained in the Introductory Note and Item 2.01 of this Current Report on Form...The information contained in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this... | 8-K5.02 | 2026-06-16 |
| Assertio Holdings, Inc.: Change in controlAs a result of Purchaser’s acceptance for payment of all Shares that were validly tendered and not validly withdrawn in accordance with the... | 8-K5.01 | 2026-06-16 |
| Assertio Holdings, Inc.: Security holder rights changeExcept as described in Item 2.01, pursuant to the Merger Agreement, each outstanding Share that was issued and outstanding immediately prio... | 8-K3.03 | 2026-06-16 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.